^
    Evidence Level:
    Sensitive: A1 - Approval

    [BRAF V600E-Colorectal Cancer-cetuximab + encorafenib]

    Source:
    FDA
    Test:

    THXID® BRAF Kit, therascreen® BRAF V600E RGQ PCR

    Published date:
    09/28/2021
    Excerpt:
    ERBITUX® is an epidermal growth factor receptor (EGFR) antagonist indicated for treatment of...BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC)...in combination with encorafenib, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy.
    Evidence Level:
    Sensitive: C4 – Case Studies

    [BRAF V600E-Hairy Cell Leukemia-vemurafenib]

    Source:
    Oncoscience
    Test:

    therascreen® BRAF V600E RGQ PCR

    Title:
    Successful re-treatment of a relapsed V600E mutated HCL patient with low-dose vemurafenib
    Excerpt:
    ...we present a successful re-treatment schema of a relapsed V600E mutated HCL with low-dose vemurafenib….We also showed that vemurafenib re-treatment of HCL patient experiencing a relapse after a first round of vemurafenib is highly efficient to induce death of leukemic cells and a quick normalization of patient's blood formulation.
    DOI:
    10.18632/oncoscience.111
    Trial ID:
    NCT01711632